Subtype
Esophageal and Gastroesophageal Junction Carcinoma
CI-CAN-00002608Explore in graph →
460 active trials11 approved drugs34 evidence items
- NCIt
- C203673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002608Explore in graph →
Clinical trials
1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (120)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01605305 | Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer | completed | Phase 2 | 60 | Fudan UniversityOTHER | 0 | May 24, 2012 | clinicaltrials |
| NCT01552980 | Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma(mSOX) | unknown | Phase 2 | 30 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 28, 2012 |
| clinicaltrials |
| NCT01095120 | Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer | unknown | Phase 2 | 27 | Genta IncorporatedINDUSTRY | 2 | Mar 15, 2012 | clinicaltrials |
| NCT01486992 | mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Jan 12, 2012 | clinicaltrials |
| NCT01402180 | Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy(Nimotuzumab) | unknown | Phase 2 / Phase 3 | 128 | Fudan UniversityOTHER | 1 | Jul 26, 2011 | clinicaltrials |
| NCT01391572 | A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer | unknown | Phase 2 | 300 | Fudan UniversityOTHER | 1 | Jul 22, 2011 | clinicaltrials |
| NCT01336049 | Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer | unknown | Phase 2 | 70 | Peking UniversityOTHER | 1 | Apr 15, 2011 | clinicaltrials |
| NCT00411151 | Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer | completed | Phase 2 | 52 | Johannes Gutenberg University MainzOTHER | 1 | Jan 20, 2011 | clinicaltrials |
| NCT00165191 | Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00239200 | Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus | terminated | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 30, 2008 | clinicaltrials |
| NCT00352833 | Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma | completed | Phase 2 | 40 | Neovii BiotechINDUSTRY | 1 | Oct 26, 2007 | clinicaltrials |
| NCT00073502 | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer | completed | Phase 2 | 43 | OSI PharmaceuticalsINDUSTRY | 3 | Feb 22, 2006 | clinicaltrials |
Data updated 22 days agoSource updated May 24, 2012source: clinicaltrials